Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases.

Lan T, Chen Y, Su Q, Ye J.

Urology. 2019 Jun 7. pii: S0090-4295(19)30507-2. doi: 10.1016/j.urology.2019.03.040. [Epub ahead of print]

PMID:
31181273
2.

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.

Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ.

Eur Urol Oncol. 2018 May;1(1):46-53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15.

PMID:
31100228
3.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
4.

Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.

Heidenreich A, Pfister D, Porres D.

J Urol. 2015 Mar;193(3):832-8. doi: 10.1016/j.juro.2014.09.089. Epub 2014 Sep 22.

PMID:
25254935
5.

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, Guminski A, Eade T.

Eur Urol Oncol. 2018 Dec;1(6):531-537. doi: 10.1016/j.euo.2018.04.017. Epub 2018 May 23.

PMID:
31158100
6.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
7.

[Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].

Heidenreich A, Pfister D, Brehmer B, Porres D.

Urologe A. 2015 Jan;54(1):14-21. doi: 10.1007/s00120-014-3697-8. German.

PMID:
25519996
8.

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy.

Guo Y, Shi D, Zhang J, Mao S, Wang L, Zhang W, Zhang Z, Jin L, Yang B, Ye L, Yao X.

J Cancer. 2019 Jan 1;10(1):81-91. doi: 10.7150/jca.27210. eCollection 2019.

9.

Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater.

Makino K, Nakagawa T, Ito E, Kasahara I, Murata T, Fujimura T, Fukuhara H, Homma Y.

Jpn J Clin Oncol. 2018 May 1;48(5):485-490. doi: 10.1093/jjco/hyy044.

PMID:
29635526
10.

Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.

Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.

Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.

PMID:
30585345
11.

Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.

Kumar A, Samavedi S, Mouraviev V, Bates AS, Coelho RF, Rocco B, Patel VR.

J Robot Surg. 2017 Mar;11(1):37-45. doi: 10.1007/s11701-016-0606-8. Epub 2016 May 31.

PMID:
27245233
12.

Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.

Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y.

Int J Urol. 1999 May;6(5):229-37; discussion 238-9.

13.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
14.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
15.

Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?

Jang WS, Kim MS, Jeong WS, Chang KD, Cho KS, Ham WS, Rha KH, Hong SJ, Choi YD.

BJU Int. 2018 Feb;121(2):225-231. doi: 10.1111/bju.13992. Epub 2017 Sep 11.

17.
18.

Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.

Park JW, Jang WS, Koh DH, Ham WS, Rha KH, Hong SJ, Choi YD.

Yonsei Med J. 2018 Jul;59(5):580-587. doi: 10.3349/ymj.2018.59.5.580.

19.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

20.

Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.

Qi P, Tsivian M, Abern MR, Bañez LL, Tang P, Moul JW, Polascik TJ.

Urol Oncol. 2013 Nov;31(8):1527-32. doi: 10.1016/j.urolonc.2012.06.003. Epub 2012 Jul 12.

PMID:
22795501

Supplemental Content

Support Center